telisotuzumab vedotin approval

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
telisotuzumab vedotin approval	1.28	0.9	4853	73	30
telisotuzumab	0.04	0.5	3045	14	13
vedotin	1.83	0.1	4964	13	7
approval	0.49	0.5	4626	17	8

Keyword	CPC	PCC	Volume	Score
telisotuzumab vedotin approval	0.45	0.9	4174	44
telisotuzumab vedotin fda approval	1.31	0.8	8443	98
polatuzumab vedotin fda approval	0.89	0.1	5782	73
polatuzumab vedotin fda approval history	1.5	0.9	8243	54
telisotuzumab vedotin teliso-v	1.21	0.8	971	41
telisotuzumab vedotin phase 3	0.06	0.7	3691	11
telisotuzumab-vedotin	1.49	0.5	4210	16
tisotumab vedotin fda approval	0.12	0.6	7734	55
polatuzumab vedotin fda label	1.64	0.3	5069	91
telisotuzumab vedotin mechanism of action	0.94	0.2	2518	53
telisotuzumab vedotin lung cancer	1.26	0.3	8950	77
telisotuzumab vedotin abbv-399	0.56	1	1131	49
disitamab vedotin fda approval	0.19	0.8	7742	1
vedolizumab subcutaneous fda approval	0.23	0.4	9632	93
brentuximab vedotin fda approval	1.11	0.8	8560	76
cost and availability of polatuzumab vedotin	1.11	0.7	6561	5
tisotumab vedotin fda label	1.06	0.8	2461	4
enfortumab vedotin fda approval	0.49	0.7	6990	14
enfortumab vedotin fda approval history	0.11	0.2	5444	51
polatuzumab vedotin patient information	1.35	0.1	4103	60
polatuzumab vedotin prescribing information	0.45	0.2	2980	82